• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Kronos Bio Inc (NQ: KRON )

    0.9833 -0.0267 (-2.64%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 74,898
    Open 0.9900
    Bid (Size) 0.9600 (20)
    Ask (Size) 1.110 (10)
    Prev. Close 1.010
    Today's Range 0.9654 - 1.020
    52wk Range 0.6900 - 1.600
    Shares Outstanding 56,769,091
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q2 2024
    KRON stock results show that Kronos Bio beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update
    From Kronos Bio, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -18.06%
    -18.06%
    1 Month
    -28.23%
    -28.23%
    3 Month
    +1.37%
    +1.37%
    6 Month
    -10.61%
    -10.61%
    1 Year
    -29.26%
    -29.26%

    More News

    Read More
    Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
    From Kronos Bio, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Recap: Kronos Bio Q4 Earnings
    Via Benzinga
    Assertio Holdings And 2 Other Penny Stocks Insiders Are Buying
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer
    From Kronos Bio, Inc.
    Via GlobeNewswire
    KRON Stock Earnings: Kronos Bio Misses EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Kronos Bio Reports First-Quarter 2024 Financial Results
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Kronos Bio, Inc.
    Via GlobeNewswire
    KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
    From Kronos Bio, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Cancer Player Kronos Bio To Stop Lanraplenib Combo Therapy Blood Cancer Study
    Via Benzinga
    Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
    From Kronos Bio, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.